Alaunos Therapeutics, Inc. (TCRT) DCF Valuation

Alaunos Therapeutics, Inc. (TCRT) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Alaunos Therapeutics, Inc. (TCRT) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Discover the true value of Alaunos Therapeutics, Inc. (TCRT) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and assess how changes affect Alaunos Therapeutics, Inc. (TCRT) valuation – all within a convenient Excel template.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .4 2.9 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 634.17 -99.83 0.04277892 0.04277892 0.04277892 0.04277892 0.04277892
EBITDA -117.2 -78.8 -75.0 -31.8 -30.9 .0 .0 .0 .0 .0
EBITDA, % 100 100 -18837.19 -1088.88 -618080 -20 -20 -20 -20 -20
Depreciation .6 1.1 2.6 2.8 2.3 .0 .0 .0 .0 .0
Depreciation, % 100 100 652.51 94.42 46300 98.88 98.88 98.88 98.88 98.88
EBIT -117.8 -80.0 -77.6 -34.6 -33.2 .0 .0 .0 .0 .0
EBIT, % 100 100 -19489.7 -1183.3 -664380 -20 -20 -20 -20 -20
Total Cash 79.7 115.1 76.1 39.1 6.1 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .1 .0 .0 .0 .0 .0
Account Receivables 3.3 4.7 1.1 .0 .0
Account Receivables, % 100 100 279.15 0.13689 20
Inventories .0 .0 .0 13.9 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 0 477 0 60 60 60 60 60
Accounts Payable .9 1.0 1.4 1.4 .6 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 343.72 47.54 12320 89.51 89.51 89.51 89.51 89.51
Capital Expenditure -.3 -9.8 -3.3 -.2 -.2 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 -834.92 -7.39 -3940 -41.48 -41.48 -41.48 -41.48 -41.48
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -177.9 -78.8 -75.7 -34.5 -33.2 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -180.0 -88.8 -72.5 -44.7 -17.9 -.6 .0 .0 .0 .0
WACC, % 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39
PV UFCF
SUM PV UFCF -.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt -6
Equity Value 6
Diluted Shares Outstanding, MM 2
Equity Value Per Share 3.46

What You Will Get

  • Real Alaunos Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Alaunos Therapeutics, Inc. (TCRT).
  • Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis.
  • Instant Valuation Updates: Automatic recalculations to assess the impact of changes on Alaunos’ fair value.
  • Versatile Excel Template: Designed for quick edits, scenario testing, and comprehensive projections.
  • Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility.

Key Features

  • Customizable Clinical Parameters: Adjust key metrics such as patient response rates, treatment costs, and trial durations.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other important financial metrics.
  • Industry-Leading Precision: Incorporates Alaunos Therapeutics’ real-world data for accurate valuation results.
  • Effortless Scenario Analysis: Easily evaluate various assumptions and analyze their impacts on outcomes.
  • Efficiency Booster: Avoid the complexities of developing intricate valuation models from the ground up.

How It Works

  1. Step 1: Download the financial analysis Excel file for Alaunos Therapeutics, Inc. (TCRT).
  2. Step 2: Review the pre-filled financial data and projections specific to Alaunos Therapeutics.
  3. Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (marked cells).
  4. Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
  5. Step 5: Evaluate the results and leverage the findings for your investment strategies.

Why Choose This Calculator for Alaunos Therapeutics, Inc. (TCRT)?

  • Designed for Experts: A sophisticated tool tailored for analysts, investors, and biotech professionals.
  • Comprehensive Data: Alaunos Therapeutics’ historical and projected financials are preloaded for enhanced precision.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions to inform your decisions.
  • Insightful Outputs: Automatically computes intrinsic value, NPV, and other essential metrics.
  • User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.

Who Should Use This Product?

  • Investors: Evaluate Alaunos Therapeutics’ (TCRT) valuation to make informed stock decisions.
  • CFOs and Financial Analysts: Enhance valuation methodologies and assess financial forecasts.
  • Startup Founders: Understand the valuation processes of biotech firms like Alaunos Therapeutics.
  • Consultants: Provide comprehensive valuation analyses and reports for clients in the healthcare sector.
  • Students and Educators: Utilize real-time industry data to teach and learn valuation strategies.

What the Alaunos Therapeutics Template Contains

  • Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Alaunos Therapeutics.
  • Real-World Data: Alaunos Therapeutics’ historical and projected financials preloaded for thorough analysis.
  • Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into financial health.
  • Key Ratios: Integrated analysis for assessing profitability, efficiency, and leverage specific to Alaunos Therapeutics.
  • Dashboard with Visual Outputs: Visualizations including charts and tables to present clear, actionable results.

No products were found matching.